Facilitating Efficient Equipment Cleaning - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Facilitating Efficient Equipment Cleaning
Equipment design and cleaning procedures both play a role in thorough sterilization and cleaning.


Pharmaceutical Technology
Volume 36, Issue 5, pp. 62-64

Equipment design pitfalls

Strong cleaning action on all product-contact surfaces minimizes the risks of contamination and of system malfunction and also enables cost-efficient cleaning. Common design pitfalls, however, impair equipment cleanability. Dead legs, pockets and crevices, air pockets, and improper equipment surfaces are pitfalls too often seen in the pharmaceutical industry.


Figure 4: Dead leg.
Dead legs. It is widely understood that dead legs should be avoided or minimized in a system (see Figure 4). Some guidance states that the length to diameter (L/D) measurement for dead legs should not be more than 2, and, in some cases, not more than 3. The relation between the main-pipe velocity and the L/D measurement, however, is often overlooked. High main-pipe velocity makes the turbulence go deeper into the dead leg, and if the turbulence or action is strong enough, it will remove the residues at the bottom of the dead leg.


Figure 5: Velocity and length/diameter measurement.
In a 1997 article, Haga et al. presented results from tests with various velocities in the main pipe in various L/D measurements (1). They found that for an L/D of 6, it is possible to clean the residue adequately if the main-pipe velocity is higher than 1.5 m/s. They also found that for an L/D of 3, it is impossible to remove the residue if the main-pipe velocity is lower than 0.7 m/s (see Figure 5).


Figure 6: A hard-to-clean pocket can be created between two metal parts an an O-ring seal.
Pockets and crevices. No rule of thumb governs the depth of pockets and crevices. Figure 6 shows a typical crevice found in pharmaceutical systems. Many guidances state that crevices should be avoided or eliminated when possible, a statement that seems weak considering that a crevice could be likened to a dead leg with an L/D measurement of 50–100, compared with the normal 2–3. Following Haga et al., it would be impossible to achieve the velocity required to clean the bottom of a crevice. Thus, pockets and crevices should not exist in pharmaceutical systems because they will always pose a major contamination risk.


Figure 7: Typical air pocket.
Air pockets. Air pockets may be described as upside-down dead legs or crevices (see Figure 7). Although residues do not collect in an air pocket, they stick to its surface. It is difficult to evacuate the air from these pockets during the cleaning process, which means that the cleaning liquid will not reach the top of the air pocket and, accordingly, will not clean it. Air pockets, therefore, must be eliminated, or they will introduce a high risk of contamination.

Surface finish. Surface finish is often considered a measurement of hygienic design. The maxim is that the smoother the surface, the more hygienic and easy to clean. But this principle is, in fact, open to debate. A 2003 study by Hilbert et al. tested the adherence of bacteria to several surfaces and the cleanability of these surfaces (2). The surfaces, from 0.1 μm electro-polished to 0.8 μm mechanically polished, showed no differences in adherence or cleanability. The main reason was the relatively large size of the individual bacteria compared with the small size of the surface imperfections. As long as the surface finish is below Ra 0.8–1.0 μm, the bacteria are too large to get trapped between the surface imperfections.

In another study, however, Riedewald showed that when bacteria accumulate in a biofilm, adherence and cleanability depend on the surface finish (3). It is hard for biofilm to attach to a smooth surface, and thus it is easy to detach them from such a surface.

The same is true for other sticky residues. A study at the Institute of Technology in Kolding, Denmark, tested the cleanability of surfaces spiked with a yogurt solution that had been oven-dried (4). This study clearly showed that a surface with a low Ra value was easier to clean than one with a high Ra value. The tested surfaces ranged from Ra 0.15 to 2.4 μm. Electropolished surfaces also were easier to clean than mechanically polished surfaces, which, in turn, are easier to clean than pickled surfaces.

Equipment designed correctly will avoid the above pitfalls, thus facilitating safe and cost-efficient cleaning. The more cleaning action is applied on all product-contact surfaces, the easier, safer, and quicker system cleaning will be.

Per-Åke Ohlsson is the global manager for Alfa Laval's Market Unit Pharma & Personal Care, Alfa Laval Lund AB, Box 74, Rudeboksvägen 1, SE-221 00 Lund, Sweden, tel. 46 46 36 74 18,
.

References

1. R. Haga et al., Pharm. Eng. 17 (5), 8–21 (1997).

2. L.R. Hilbert et al., Int. Biodeterior. Biodegradation 52 (3), 175–185 (2003).

3. F. Riedewald, PDA J. Pharm. Sci. Technol. 60 (3), 164–171 (2006).

4. D. Bagge-Rawn, Microbial Adhesion and Biofilm Formation in the Food Processing Industry (Technical University of Denmark, Kolding, Denmark, 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here